agilon health, inc. (NYSE:AGL) Given Average Rating of “Reduce” by Brokerages

agilon health, inc. (NYSE:AGL) has earned a consensus rating of “Reduce” from the twenty analysts that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $6.05.

AGL has been the topic of several research reports. Evercore ISI decreased their price objective on shares of agilon health from $7.00 to $4.00 and set an “in-line” rating on the stock in a report on Tuesday, October 8th. Stifel Nicolaus decreased their price objective on shares of agilon health from $7.00 to $2.00 and set a “hold” rating on the stock in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of agilon health from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, August 9th. TD Cowen decreased their price target on shares of agilon health from $6.00 to $2.00 and set a “hold” rating on the stock in a research note on Monday, November 11th. Finally, Benchmark restated a “buy” rating and issued a $9.00 price target on shares of agilon health in a research note on Thursday, August 8th.

agilon health Price Performance

NYSE:AGL opened at $2.10 on Friday. agilon health has a one year low of $1.50 and a one year high of $13.76. The company has a market cap of $865.24 million, a P/E ratio of -2.23 and a beta of 0.60. The firm’s fifty day moving average price is $2.76 and its two-hundred day moving average price is $4.66. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.29 and a quick ratio of 1.29.

agilon health (NYSE:AGL) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.19). agilon health had a negative net margin of 6.88% and a negative return on equity of 47.84%. The company had revenue of $1.45 billion during the quarter, compared to analyst estimates of $1.47 billion. During the same quarter in the prior year, the firm earned ($0.06) earnings per share. Equities analysts expect that agilon health will post -0.47 earnings per share for the current year.

Insider Buying and Selling at agilon health

In other news, CEO Steven Sell bought 20,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $3.36 per share, with a total value of $67,200.00. Following the transaction, the chief executive officer now owns 67,590 shares of the company’s stock, valued at $227,102.40. This trade represents a 42.03 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.20% of the company’s stock.

Institutional Trading of agilon health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citigroup Inc. grew its position in shares of agilon health by 2,251.5% during the 3rd quarter. Citigroup Inc. now owns 2,028,246 shares of the company’s stock worth $7,971,000 after buying an additional 1,941,993 shares during the period. AQR Capital Management LLC grew its position in shares of agilon health by 3,338.5% during the 2nd quarter. AQR Capital Management LLC now owns 1,356,438 shares of the company’s stock worth $8,871,000 after buying an additional 1,316,990 shares during the period. Quantbot Technologies LP acquired a new stake in shares of agilon health during the 3rd quarter worth approximately $1,742,000. Vanguard Group Inc. grew its position in shares of agilon health by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 28,947,798 shares of the company’s stock worth $176,582,000 after buying an additional 371,537 shares during the period. Finally, Susquehanna Fundamental Investments LLC grew its position in shares of agilon health by 65.0% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 804,594 shares of the company’s stock worth $5,262,000 after buying an additional 316,856 shares during the period.

About agilon health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.